Pfizer stock rises as CEO bets on “Viagra-like” obesity demand; what investors watch next
Pfizer shares rose 1.7% to close at $25.58 on Wednesday, driven by investor focus on its push into obesity drugs. CEO Albert Bourla said Pfizer will launch 10 Phase 3 trials for Metsera compounds this year. After-hours trading was quiet. Investors await Pfizer’s results update on Feb. 3 and the ex-dividend date on Jan. 23.